参考文献/References:
[1] 杨慧霞.妊娠期精代谢异常孕妇并发子痫期的相关因素探讨[J].中华妇产科杂志,2005,40(9):577.
[2] 胡春玲,罗毅平,李莉群,等.妊娠糖尿病与炎症因子关系的研究[J].江西医学院学报,2006,46(2):62-67.
[3] Bloomgarden ZT.Inflammation and insulin resistance[J].Diabetes Care,2003,26(5):1619-1623.
[4] 吴连方.妊娠糖尿病的筛查与诊断[J].中华全科医师杂志, 2005.4(8):462-463.
[5] Haffner SM,Miettinen H,Stern MP.The homeostasis model in the San Antonio Heart Study[J].Diabetes Care,1997,20(7):1087-1092.
[6] Kekki M,Kurki T,Kotomaki T,et al.Cost.effectiveness of screening and treatment for bacterial vaginosis in early pregnancy among women at low risk for preterm birth[J].Acta Obstet Gynecol Scand,2004,83(1):27-36.
[7] Harris SB,Caultleld LE,Sugamori ME,et al.The epidemiology of diabetes in pregnant Native Canadians.A risk prof ile[J].Diabetes Care,1997,20(9):1422-1425.
[8] 李文.产科领域的胰岛素抵抗[J].国外医学妇幼保健分册, 2003,14(2):65-68.
[9] Akbay E,Tiras MB,Yetkin I,et al.Insulin secretion and insulin sensit-iveity in normal pregnancy and gestafional diabetes mellitus[J].Gyneeol Endocrinol,2003,17(2):137-142.
[10] Retnakaran R,Hanley AJ,Raif N,et al.C-reactive protein and gestati-onal diabetes:the central role of maternal obesity[J].J Clin Endocrinol Metab,2003,88(8):3507-3512.
[11] Atèqbo JM,Grissa O,Yessoufou A,et al.Modulation of adipokines and cytokines in gestational diabetes and macrosomia[J].J Clin Endocrinol Metab,2006,91(10):4137-4143.
[12] Qiu c,Sorensen TK,Luthy DA,et al.A prospective study of maternal serum C-reactive protein (CRP) eoneentrations and risk of gestational diabetes mellitus[J].Paediatr Perinat Epidemiol,2004, 18(5):377-384.
相似文献/References:
[1]梁雯丽,郑艳,李娜,等.Graves甲亢患者131I治疗后早期TRAb及TSAb变化的研究分析[J].国际放射医学核医学杂志,2016,40(1):13.[doi:10.3760/cma.j.issn.1673-4114.2016.01.003]
Liang Wenli,Zheng Yan,Li Na,et al.Analysis of the changes in early TRAb and TSAb after 131I treatment for patients with Graves hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(4):13.[doi:10.3760/cma.j.issn.1673-4114.2016.01.003]
[2]李景涛,邓垒,张文珏,等.广泛期小细胞肺癌胸部IMRT后发生放射性肺炎的危险因素分析[J].国际放射医学核医学杂志,2016,40(2):100.[doi:10.3760/cma.j.issn.1673-4114.2016.02.003]
Li Jingtao,Deng Lei,Zhang Wenjue,et al.Risk factor analysis for predicting radiation pneumonitis in extensive stage small cell lung cancer patients receiving IMRT thoracic radiotherapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(4):100.[doi:10.3760/cma.j.issn.1673-4114.2016.02.003]
[3]刘佳,高刚,朴春南,等.调节肿瘤放射敏感性的miRNAs研究进展[J].国际放射医学核医学杂志,2016,40(2):159.[doi:10.3760/cma.j.issn.1673-4114.2016.02.015]
Liu Jia,Gao Gang,Piao Chunnan,et al.Progress of microRNAs in regulating tumor radiation sensitivity[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(4):159.[doi:10.3760/cma.j.issn.1673-4114.2016.02.015]
[4]陈晓艳,张江虹,邵春林.STAT3与辐射敏感相关性的研究进展[J].国际放射医学核医学杂志,2016,40(3):191.[doi:10.3760/cma.j.issn.1673-4114.2016.03.007]
Chen Xiaoyan,Jianghong,Shao Chunlin.Research progresses of correlation between STAT3 and radiosensitivity[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(4):191.[doi:10.3760/cma.j.issn.1673-4114.2016.03.007]
[5]赵德云,李百龙.植物提取物防治放射性肺损伤的现状与展望[J].国际放射医学核医学杂志,2016,40(3):208.[doi:10.3760/cma.j.issn.1673-4114.2016.03.010]
Zhao Deyun,Li Bailong.Protective and therapeutic effects of plant extracts on radiation-induced lung injury:present status and future prospects[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(4):208.[doi:10.3760/cma.j.issn.1673-4114.2016.03.010]
[6]邓艳,张伟.125I-碘酞酸盐临床应用进展[J].国际放射医学核医学杂志,2016,40(3):225.[doi:10.3760/cma.j.issn.1673-4114.2016.03.012]
Deng Yan,Zhang Wei.125I-iothalamate clinical applications[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(4):225.[doi:10.3760/cma.j.issn.1673-4114.2016.03.012]
[7]邓大平,卢峰,孙洪强,等.颅脑肿瘤放射治疗时射野外器官吸收剂量体模法测量与分析[J].国际放射医学核医学杂志,2016,40(4):272.[doi:10.3760/cma.j.issn.1673-4114.2016.04.007]
Deng Daping,Lu Feng,Sun Hongqiang,et al.Test and analysis of out-of-field organ dose in intracranial tumor radiotherapy using phantom[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(4):272.[doi:10.3760/cma.j.issn.1673-4114.2016.04.007]
[8]杨珂,唐波,于夕荣,等.甲状腺癌131i治疗病房的辐射屏蔽计算与评价[J].国际放射医学核医学杂志,2015,39(5):405.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 012]
yang ke,tang bo,yu xirong,et al.shielding calculation and assessment in 131i therapy for thyroid cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(4):405.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 012]
[9]赵舒怡,储小飞,樊赛军.血清肿瘤标志物与肿瘤放疗疗效评估的研究进展[J].国际放射医学核医学杂志,2015,39(5):427.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 018]
zhao shuyi,chu xiaofei,fan saijun..progression of study on serum tumor markers in evaluation of tumor radiotherapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(4):427.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 018]
[10]赵徵鑫,翟贺争,张文艺,等.质子重离子治疗肿瘤的进展[J].国际放射医学核医学杂志,2016,40(5):384.[doi:10.3760/cma.j.issn.1673-4114.2016.05.010]
Zhao Zhixin,Zhai Hezheng,Zhang Wenyi,et al.Development of proton heavy ion in tumor therapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(4):384.[doi:10.3760/cma.j.issn.1673-4114.2016.05.010]
[11]田琦,蒋宁一,郑丽.265例精细个体化131I治疗Graves甲亢的疗效观察[J].国际放射医学核医学杂志,2016,40(4):259.[doi:10.3760/cma.j.issn.1673-4114.2016.04.004]
Tian Qi,Jiang Ningyi,Zheng Li.Therapeutic effect of fine individual 131I treatment on Graves disease hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(4):259.[doi:10.3760/cma.j.issn.1673-4114.2016.04.004]
[12]汤建林,李玉莹,高柳艳,等.131I治疗Graves病规范化建设体会[J].国际放射医学核医学杂志,2011,35(3):179.[doi:10.3760/cma.j.issn.1673-4114.2011.03.011]
TANG Jian-lin,LI Yu-ying,GAO Liu-yan,et al.Standardization of 131I therapy for Graves disease[J].International Journal of Radiation Medicine and Nuclear Medicine,2011,35(4):179.[doi:10.3760/cma.j.issn.1673-4114.2011.03.011]
[13]孟召伟,谭建.解读美国甲状腺协会和临床内分泌医师协会2011年甲亢诊治指南[J].国际放射医学核医学杂志,2011,35(4):193.[doi:10.3760/cma.j.issn.1673-4114.2011.04.001]
MENG Zhao-wei,TAN Jian.Reading and analysis on management guidelines for hyperthyroidism published in 2011 by American Thyroid Association and American Association of Clinical Endocrinologists[J].International Journal of Radiation Medicine and Nuclear Medicine,2011,35(4):193.[doi:10.3760/cma.j.issn.1673-4114.2011.04.001]
[14]卢建林,侯建全,杨永青.125I-脱氧尿苷治疗膀胱癌的实验与临床研究[J].国际放射医学核医学杂志,2009,33(3):154.[doi:10.3760/cma.j.issn.1673-4114.2009.03.007]
LU Jian-lin,HOU Jian-quan,YANG Yong-qin.Experimental and clinical treatment of bladder cancer with 125I-iododeoxyuridine[J].International Journal of Radiation Medicine and Nuclear Medicine,2009,33(4):154.[doi:10.3760/cma.j.issn.1673-4114.2009.03.007]
[15]阎军艳,李险峰.放射治疗在晚期甲状腺乳头状癌中的研究进展[J].国际放射医学核医学杂志,2017,41(1):59.[doi:10.3760/cma.j.issn.1673-4114.2017.01.011]
Yan Junyan,Li Xianfeng.Role of radiation therapy in the treatment of advanced papillary thyroid carcinoma and its research progress[J].International Journal of Radiation Medicine and Nuclear Medicine,2017,41(4):59.[doi:10.3760/cma.j.issn.1673-4114.2017.01.011]
[16]林琛,王鲁华,李俊雄,等.131Ⅰ治疗Graves’甲状腺亢进症伴白细胞减少前后血清和尿中β2-微球蛋白变化分析[J].国际放射医学核医学杂志,2007,31(2):98.
LIN Chen,WANG Lu-hua,LI Jun-xiong,et al.Changes of serum and urine β2-microglobulin of leukopenia in hyperthyroidism of Graves’ disease before and after 131Ⅰ therapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2007,31(4):98.
[17]崔丽群,张承刚,李玲玲.小剂量131I治疗青少年Graves’病85例患者疗效观察[J].国际放射医学核医学杂志,2007,31(4):226.
CUI Li-qun,ZHANG Cheng-gang,LI Ling-ling.The observation of curative effects by therapy with low-dose 131I in younger with Graves’ disease[J].International Journal of Radiation Medicine and Nuclear Medicine,2007,31(4):226.
[18]覃伟武.131Ⅰ治疗非Graves’甲状腺功能亢进及非毒性甲状腺肿后诱发Graves’病[J].国际放射医学核医学杂志,2006,30(6):325.
QIN Wei-wu.Induction of Graves’ disease in patients with non-autoimmune hyperthyroidism or nontoxic goiter after radioiodine treatment[J].International Journal of Radiation Medicine and Nuclear Medicine,2006,30(4):325.
[19]陆克义,李险峰,段炼,等.Graves’病患者131Ⅰ治疗后对其周围人群辐射当量剂量的评估[J].国际放射医学核医学杂志,2006,30(6):347.
LU Ke-yi,LI Xian-feng,DUAN Lian,et al.Evaluation of the dose equivalent from patients with Graves’ disease after 131Ⅰ therapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2006,30(4):347.
[20]秦岚,邵梦麟,王俊起.小剂量131I治疗甲亢的对比研究[J].国际放射医学核医学杂志,2005,29(3):112.
QIN lan,SHAO Meng-lin,WANG Jun-qi.Comparative study of low dose 131I treatment in patients with Graves’ disease[J].International Journal of Radiation Medicine and Nuclear Medicine,2005,29(4):112.